Nearly 75% of deceased former NFL players examined in a new study showed signs of chronic traumatic encephalopathy (CTE), a neurodegenerative disease linked to repeated head impacts.
The findings, published in the journal JAMA Network Open, suggest that while previous research may have overestimated the disease’s prevalence due to selection bias, the burden of the condition among former professional football players remains high. Researchers analyzed data from 2,362 former players who participated in at least one NFL regular or postseason game and died between January 2008 and December 2023. The study utilized records from the UNITE Brain Bank at Boston University and the National Death Index to account for the fact that brain donations are not random.
Because families of players who exhibited cognitive, mood, or behavioral symptoms during their lifetimes are more likely to donate the brain for research, earlier studies faced a selection bias.
“The selection bias has a substantial inflationary impact on disease prevalence estimates when estimates are based on brains donated because of the disease in question,” the authors said in their analysis. By adjusting for these factors, the researchers reduced the estimated prevalence from the 93.5% observed in donor samples to a population-wide estimate of 74.5%.
The data highlighted distinct differences between the 396 brain donors and the 1,966 non-donors in the study. Donors died at a younger average age of 67, compared to 74.7 years for non-donors. Donors also played in the league for a longer duration, averaging 7.1 years versus 4.7 years for non-donors, and were more likely to have a death certificate that recorded a dementia-related cause.
The study also estimated that 27.2% of the deceased player population had a history of all-cause dementia. This figure is significantly higher than the 8.9% reported in the NFL-LONG study, which surveyed living former players over the age of 50. The authors clarified that these two metrics are not directly comparable, as the current study assessed lifetime history among the deceased, whereas the previous research examined a living cohort that includes younger individuals who may develop symptoms later.
While the study provides a clearer picture of the neuropathology at the time of death, the researchers said that their classification relied on clinical indicators rather than direct evaluations, which can lead to uncertainties when CTE and symptom status do not align.
The study estimated that 74.5% of the population had CTE, but this includes all stages of the disease, some of which may be early-stage or asymptomatic. The authors have proposed their methodology as a framework for future autopsy studies where participant selection is influenced by clinical symptoms.
Keep reading